Urology
Volume 73, Issue 5, Supplement , Pages S28-S35 , May 2009

Current Prostate Cancer Treatments: Effect on Quality of Life

Received 2 February 2009 ,Accepted 6 March 2009.

References 

  1. Garcia M, Jemal A, Ward E, et al. Global cancer facts and figures 2007. http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdf2007;Accessed May 23, 2008
  2. Ries L, Melbert D, Drapcho M, et al. SEER cancer statistics review (based on November 2007 SEER data submission, posted to the SEER Web site, 2008). http://seer.cancer.gov/csr/1975_2005/Accessed May 30, 2008
  3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  4. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131
  5. Mohler J, Bahnson R, Boston B, et al. NCCN Clinical Practice Guidelines in Oncology Prostate cancer. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdfFebruary 21, 2008;Accessed May 23, 2008
  6. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  7. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984
  8. Shelley MD, Kumar S, Wilt T, et al. A systematic review and metal-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2008;35:9–17
  9. Gomella LG. Addressing the needs of the high-risk prostate cancer patient. Rev Urol. 2005;7(suppl 5):S18–S28
  10. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008;18:613–620
  11. Hu JC, Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008;26:2278–2284
  12. Blute ML. Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?. J Clin Oncol. 2008;26:2248–2249
  13. Jani AB, Su A, Correa D, et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis. 2007;10:82–86
  14. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(suppl 5):S37–S43
  15. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90:427–432
  16. Rosenblatt DE, Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract. 1995;8:317–320
  17. Sharpley CF, Christie DR. An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer. Psycho-oncol. 2007;16:660–667
  18. Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int. 2007;99(suppl 1):25–29
  19. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–244
  20. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426–4434
  21. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol. 2008;179:414–423
  22. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–132
  23. Thorpe JF, Jain S, Marczylo TH, et al. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl. 2007;89:207–211
  24. Simoneau AR. Treatment- and disease-related complications of prostate cancer. Rev Urol. 2006;8(suppl 2):S56–S67
  25. Wu AK, Cooperberg MR, Sadetsky N, et al. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008;180:2415–2422
  26. Chen RC, Clark JA, Manola J, et al., JA  Treatment “mismatch” in early prostate cancer: do treatment choices take patient quality of life into account?. Cancer. 2008;112:61–68
  27. Clark JA, Talcott JA. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. J Clin Oncol. 2006;24:4457–4463
  28. Carlsson S, Aus G, Wessman C, et al. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA)—results from a prospective, population-based, randomised study. Eur J Cancer. 2007;43:2109–2116
  29. Taupin D, Chambers SL, Corbett M, et al. Colonoscopic screening for colorectal cancer improves quality of life measures: a population-based screening study. Health Qual Life Outcomes. 2006;4:82–87
  30. Arcangeli CG, Ornstein DK, Keetch DW, et al. Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am. 1997;24:299–306
  31. Katz DA, Jarrard DF, McHorney CA, et al. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology. 2007;69:215–220
  32. Love AW, Scealy M, Bloch S, et al. Psychosocial adjustment in newly diagnosed prostate cancer. Aust N Z J Psychiatry. 2008;42:423–429
  33. Rosenfeld B, Roth AJ, Gandhi S, et al. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncol. 2004;13:800–807
  34. Awsare NS, Green JS, Aldwinckle B, et al. The measurement of psychological distress in men being investigated for the presence of prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:384–389
  35. Katz A, Katz A. The top 13: what family physicians should know about prostate cancer. Can Fam Physician. 2008;54:198–203
  36. Bellizzi KM, Latini DM, Cowan JE, et al. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology. 2008;72:1269–1273
  37. Arredondo SA, Downs TM, Lubeck DP, et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2008;179(suppl):S14–S18
  38. National Cancer Institute. Observation or radical treatment in patients with prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00499174Accessed December 20, 2008
  39. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  40. Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597–601
  41. Hinz A, Krauss O, Stolzenburg JU, et al. Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study. Urol Oncol. Epub 2008 April 25.
  42. Bacon CG, Giovannucci E, Testa M, et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862–871
  43. Eller LS, Lev EL, Gejerman G, et al. Prospective study of quality of life of patients receiving treatment for prostate cancer. Nurs Rev. 2006;55(suppl):S28–S36
  44. Fletcher BS, Paul SM, Dodd MJ, et al. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer. J Clin Oncol. 2008;26:599–605
  45. National Cancer Institute. Cancer trends progress report—2007 update. http://progressreport.cancer.gov2007;Accessed December 20, 2008
  46. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100:888–897
  47. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518–527
  48. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18:51–76
  49. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828–841
  50. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4:643–656
  51. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2008;301:39–51
  52. Avodart® (dutasteride) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2008;
  53. Proscar® (finasteride) prescribing information. Whitehouse Station, NJ: Merck & Company; 2007;
  54. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  55. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–541
  56. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt. 1):1399–1403
  57. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–441
  58. McConnell JD, Bruskewitz R, Walsh P, et al. Finasteride Long-Term Efficacy and Safety Study Group The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–563
  59. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J Clin Oncol. 2009;27:1502–1516
  60. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008;112:1058–1065

 L. G. Gomella serves as a consultant and investigator for GlaxoSmithKline and as a consultant to Watson Pharmaceuticals; E. J. Trabulsi serves as a paid consultant to Intuitive Surgical; J. Johannes has no conflicts to report.

PII: S0090-4295(09)00316-1

doi: 10.1016/j.urology.2009.03.003

Urology
Volume 73, Issue 5, Supplement , Pages S28-S35 , May 2009

Article Tools